SUMMARY The effect of a new complex oligosaccharide exhibiting potent inhibitory action on ax-glucoside hydrolases on intestinal absorption of sucrose in man was tested by constant in vivo perfusion of the jejunum. At concentrations of 4-65 or 155 x 10-6M the ac-glucosidehydrolase inhibitor (a-GHI) markedly inhibited absorption of glucose from sucrose and absorption of sodium and water. Oral administration of the a-GHI resulted as well in depression of solute, sodium, and water absorption. This new compound can serve as an interesting tool to induce carbohydrate malabsorption by inhibition of final digestion and may possibly be of beneficial therapeutic effect in dietary control of diabetes or obesity.
Terminal digestion of carbohydrates by x-glucosidehydrolases and absorption of hydrolytic products are closely linked processes at the brush border membrane of mucosal epithelial cells (Gray, 1975; Crane, 1975; Caspary, 1977a) . A recently described complex oligosaccharide of microbial origin (molecular weight 645) was found to possess potent inhibitory action on ox-glucosidehydrolases from pig intestine (Schmidt et al., 1977) . The Ki of this potent a-glucosidehydrolase inhibitor (ac-GHI) was found to be 1P3 x 10-6M versus sucrase from human intestinethat is, the inhibitor had a more than 10 000-fold higher affinity to the enzyme sucrase than its natural substrate sucrose . The affinity (Ki) of this oligosaccharide to intestinal sucrase is therefore in the order of magnitude of phlorizininteraction with the glucose carrier in the brush border membrane (Alvarado and Crane, 1962) .
This study was designed to test whether the ax-GHI will inhibit absorption of glucose derived from sucrose in healthy human volunteers under conditions of in vivo intestinal perfusion.
Methods

GENERAL
Intestinal perfusion studies were performed in 10
Receih ed for publication 5 June 1979 healthy volunteers (mean age: 25 ±7 years) who were informed about the detai's of the study and gave written consent. Approval for the study was given by a local University Ethical Committee. Two different designs of studies were used: (1) perfusion of a 30 cm jejunal segment with a double lumen tube incorporating a proximal occluding balloon to test the direct effect of the x-GHI in the perfusate on intestinal absorption of glucose from sucrose, water, and sodium; (2) perfusion of a 30 cm jejunal segment with a triple lumen tube containing a 10 cm mixing segment in order to follow the effect of oral administration of the oc-GHI on intestinal absorption.
STUDY I (Fig. 1 
Results
The presence of 3 or 10 t±g/ml (=4-65 or 155x
10-6M) of the ac-GHI resulted in a marked decrease of net jejunal absorption of glucose from sucrose, sodium, and water (Fig. 2) (Figs. 2 and 3) . Oral administration of 300 mg of the c-GHI dissolved in 75 ml of water resulted in decreased absorption of glucose from sucrose during the third 10 minute sampling period after oral cx-GHI administration (Fig. 3) . The inhibitory effect of oc-GHI administration persisted up to 170 minutes (110 minutes after administration of the ac-GHI) (Fig. 3) . A similar pattern of inhibition was observed for water and sodium absorption (Figs. 4 and 5) . At 100 minutes a slight net secretion of water and sodium was found (40 minutes after ac-GHI-administration).
Discussion
Intestinal absorption of hexoses may be depressed in humans by biguanides (Arvanitakis et al., 1973; Caspary, 1977b) , prenylamine (Caspary and Creutzfeldt, 1972; Gottesburen et al., 1974) , and aspirin (Arvanitakis et al., 1977) . Inhibition of sodiumdependent active hexose transport by depriving mucosal cells of energy seems to be the underlying mechanism responsible for the inhibitory action of biguanides and aspirin on intestinal glucose absorption (Arvanitakis et al., 1977; Caspary, 1977b) . Another approach to inhibit glucose absorption (from sucrose) has been reported with the use of TRIS which is a competitive inhibitor of sucrase (Puls and Keup, 1975) . A recently developed new cx-glucosidehydrolase inhibitor possessed potent inhibitory action on ao-glucosidase activities from pig small intestine (Schmidt et al., 1977) , rat and human small intestine (Caspary, 1978a; Caspary et al., 1978) . This potent inhibitor of human yamylase, sucrase, and maltase has an affinity to sucrase which lies in the same range phlorizin interacts with the glucose carrier binding site (Alvarado and Crane, 1962) . It should therefore be able to decrease intestinal absorption of glucose from disaccharides, especially from sucrose. Oral loading with sucrose or maltose in humans resulted in a decrease of postprandial hyperglycaemia when the ac-glucosidehydrolase inhibitor was given, thus suggesting inhibition or delay of absorption (Puls et al., 1977; Caspary, 1978b (Fig. 2) . Decreased absorption of disaccharides in lactase-or sucrase-isomaltase deficient subjects (Launiala, 1968; Kern and Struthers, 1966) or of D-glucose after pretreatment with phenformin (Arvanitakis et al., 1973) resulted in a considerably more extensive inhibition or even in secretion of net water and sodium transport than reduction of solute (glucose) absorption. Thus the unsplit disaccharides exerted an osmotic effect which may induce secretion of water depending on the amount of maldigested disaccharides (Launiala, 1968) . As in vitro studies with rat intestine (Caspary, 1978a) have shown that the o-GHI interferes only with o-glucosidehydrolases (y-amylase, sucrase, maltase), but not with the intestinal active hexose transport system itself, it can be assumed that inhibition of glucose absorption from sucrose was due to inhibition of absorption of the hydrolytic products of sucrose. Pilot studies performed in three patients had shown that the presence of 15 5 x 10.6M oc-GHI in the perfusate did not affect absorption of free glucose. As, in addition, concentration of free glucose measured in the aspirate was minimal in the presence and in the absence of the o-GHI, it can be concluded that inhibition of glucose absorption from sucrose was entirely due to inhibition of sucrose hydrolysis. The aim of the second study (study II) was to test how long the inhibitor's action would persist after a single oral dose. Initially, it was intended to take small bowel biopsies at different time intervals after an oral dose of the inhibitor in order to measure inhibition of oc-glucosidases in the biopsy tissue. The flushing buffer volume to obtain the biopsies by an hydraulic biopsy device and the dilutions during processing of the biopsy material for enzyme analysis would certainly have resulted in dissociation of the competitive inhibitor from the enzymes. We therefore used the constant perfusion technique with a non-absorbable marker (triple lumen technique). This technique requires steady state conditionsthat is, a constant concentration of dilutional marker in the perfusate . The steady state requirement was fulfilled during the control period when sucrose alone was perfused with the marker (PEG 4000). Levitt and Bond (1977) have clearly pointed out that the constant perfusion technique in the non-steady state may lead to errors. After administration of the a-GHI with 75 ml of water, steady state conditions were apparently no longer maintained because of the volume of water added and the concentration-dependent action of the inhibitor on sucrose hydrolysis. Nevertheless, we used the constant perfusion technique in the nonsteady state because we could not think of any other approach to answer the question posed in study II. The magnitude of inhibition of glucose absorption from sucrose, of absorption of water and sodium was so high that possible errors imposed by the nonsteady state seem to be negligible.
Inhibition of glucose absorption from sucrose was more pronounced after oral administration of 300 mg of the a.-GHI than by direct and constant presence of 10 ,ug/ml of the o-GHI in study I. The actual concentration of the oc-GHI during perfusion in study II is not known, but assuming dilution of the oc-GHI by at least 1000 ml of water, gastric, pancreatic, and biliary secretions and perfusate it could be deduced that at least for some time of the perfusion period the concentration might have reached 300 ,ug/ml, a concentration 30-fold higher than under the conditions of study I.
Additional studies in the meantime have shown that administration of the a-GHI to humans not only induced a delay of glucose absorption from sucrose but resulted in malabsorption of sucrose measured by massive breath hydrogen production; this was observed in subjects ingesting 100 g of sucrose together with 200 mg of the a-GHI (Caspary, 1978b) in the same way as in patients with hyposucrasia ingesting sucrose (Metz et al., 1976) . Six of the 10 volunteers undergoing study I and five out of 10 participating in study II developed diarrhoea and flatulence toward the end of the perfusion period.
The new o-GHI can serve as an interesting tool to mimic final maldigestion of o-glucosides without affecting monosaccharide absorption. It is possible that the inhibitor may prove to be of benefit in the dietary control of diabetes or obesity and it is currently being tested by several European groups. A dose response study will have to show whether a delay of glucose absorption from carbohydrates induced by the oc-GHI without inducing malabsorption still has beneficial effects in reducing postprandial blood glucose. 
